Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)

International Journal of Cardiovascular Imaging

Volumn 28, Issue 3, 2012, Pages 455-465

  García García, Héctor M ^a,b   Garg, Scot ^a   Brugaletta, Salvatore ^a   Morocutti, Giorgio ^c   Ratner, Robert E ^d   Kolatkar, Nikheel S ^e   Kravitz, Barbara G ^e   Miller, Diane M ^e   Huang, Chun ^e   Nesto, Richard W ^f   Serruys, Patrick W ^a   Aftring, R P ^g   Kolatkar, N ^g   Kravitz, B ^g   Wolstenholme, A ^g   Saarinen, K ^g   Fowler, R ^g   Hoffman, Janet ^g   Steele Norwood, D ^g   Russell, R ^g   Young, S ^g   Chou, Hubert ^g   McMorn, Steve ^g   Kirsch, Courtney ^g   Louridas, Bonnie ^g   Olivieria, Teresa ^g   Mattioli, Debra ^g   Miller, D ^g   Huang, C ^g   Nguyen, C ^g   Jahnke, L ^g   Mintz, G ^g   Lachin, J ^g   Abrahamson, M ^g   Carson, P ^g   Jones, P ^g   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIALYSIS   (Netherlands)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e GLAXOSMITHKLINE   (United States)

^f LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^g NONE

Author keywords

Atherosclerosis; IVUS; Restenosis; Type 2 diabetes

Indexed keywords

GLIPIZIDE; ROSIGLITAZONE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEOINTIMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; FEMALE; GLIPIZIDE; HUMANS; HYPERPLASIA; HYPOGLYCEMIC AGENTS; MALE; METALS; MIDDLE AGED; NEOINTIMA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; STENTS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84861478702     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-011-9836-z     Document Type: Article

References (36)

1. Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ (2008) Assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history (approach): Study design and baseline characteristics. Am Heart J 156(6):1074-1079. doi:10.1016/j.ahj.2008.07.025
2. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garcia- Garcia HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease. The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. doi:10.1161/ CIRCULATIONAHA.109.881003
3. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB (1998) The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32(3):584-589. doi:S0735-1097(98)00286-1
4. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, de Feyter PJ, van Domburg RT, Serruys PW (2004) Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: An evaluation from the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (research) study. Circulation 109(11):1366-1370. doi:10.1161/01.CIR. 0000121358.26097.06 (Pubitemid 38387822)
5. Scheen AJ, Warzee F, Legrand VM (2004) Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 25(23): 2167-2168; author reply 2168-2169. doi:10.1016/j.ehj.2004.07.041
6. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW (2004) Impact of sirolimus-eluting stents on outcome in diabetic patients: A sirius (sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109(19):2273-2278. doi:10.1161/01.CIR.0000129767.45513.71 (Pubitemid 38678518)
7. Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K, Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M, Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, Yoshikawa J (2009) A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: Popps (prevention of in-stent neointimal proliferation by pioglitazone study). JACC Cardiovasc Interv 2(6):524-531. doi:10.1016/j.jcin.2009.04.007
8. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J (2003) Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: An intravascular ultrasound scanning study. Am Heart J 146(2):E5. doi:10.1016/S0002-8703(03) 00146-7
9. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA (2000) Expression and function of ppargamma in rat and human vascular smooth muscle cells. Circulation 101(11):1311-1318 (Pubitemid 30158620)
10. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS (2004) Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27(11):2654-2660. doi:27/11/2654
11. Geng DF, Jin DM, Wu W, Wang Z, Wang JF (2009) Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: A meta-analysis of randomized controlled trials. Atherosclerosis 202(2):521-528. doi:10.1016/j.atherosclerosis.2008.05.029
12. Katayama T, Ueba H, Tsuboi K, Kubo N, Yasu T, Kuroki M, Saito M, Momomura S, Kawakami M (2007) Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 153(5):762 e761-762 e767. doi:10.1016/j.ahj.2007.02.022
13. Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M (2005) Pioglitazone reduces neointima volume after coronary stent implantation: A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112(18):2792-2798. doi:10.1161/CIRCULATIONAHA. 105.535484 (Pubitemid 41641673)
14. Osman A, Otero J, Brizolara A, Waxman S, Stouffer G, Fitzgerald P, Uretsky BF (2004) Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 147(5):e23. doi:10.1016/j.ahj.2003. 12.006
15. Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T (2006) A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 29(1):101-106. doi:29/1/101
16. Rodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM, de Winter S, Ligthart JM, Deckers JW, Bertrand M, Simoons ML, Ferrari R, Fox KM, Remme W, De Feyter PJ (2007) Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [perspective] study). Am J Cardiol 100(2):159-163. doi:10.1016/j.amjcard.2007. 02.073 (Pubitemid 47049630)
17. De Winter SA, Hamers R, Degertekin M, Tanabe K, Lemos PA, Serruys PW, Roelandt JR, Bruining N (2004) Retrospective image-based gating of intracoronary ultrasound images for improved quantitative analysis: The intelligate method. Catheter Cardiovasc Interv 61(1):84-94. doi:10.1002/ccd.10693 (Pubitemid 38036796)
18. Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K, Schiele F, Russell ME, Koglin J, Serruys PW (2005) Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: Insights from serial intravascular ultrasound analysis in the taxus ii study. Circulation 112(25):3876-3883. doi:10.1161/CIRCULATIONAHA.105.558601 (Pubitemid 43739485)
19. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P (2007) Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 370(9591):937-948. doi:10.1016/S0140-6736(07)61444-5 (Pubitemid 47393576)
20. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R (2007) Effectiveness and safety of drug-eluting stents in ontario. N Engl J Med 357(14):1393-1402. doi:10.1056/NEJMoa071076 (Pubitemid 47541971)
21. Windecker S, Juni P (2008) Safety of drug-eluting stents. Nat Clin Pract Cardiovasc Med 5(6):316-328. doi:10.1038/ncpcardio1189 (Pubitemid 351761706)
22. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 369(9562):667-678. doi:10.1016/S0140-6736(07)60314-6 (Pubitemid 46281313)
23. Kereiakes DJ, Young JJ (2005) Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents. Rev Cardiovasc Med 6(Suppl 1):S48-S58 (Pubitemid 40227687)
24. Aronson D, Bloomgarden Z, Rayfield EJ (1996) Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 27(3):528-535. doi:0735-1097(95)00496-3
25. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 287(19):2570-2581. doi:jrv10119
26. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, Timmis GC, Balasubramaniam M, O'Neill WW (2004) Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type ii diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 43(1):8-14. doi:S073510970301324X
27. Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE (1999) Troglitazone inhibits angiotensin ii-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 452(3):277-282. doi:S0014-5793(99)00624-9
28. Yasunari K, Kohno M, Kano H, Yokokawa K, Minami M, Yoshikawa J (1997) Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 81(6):953-962 (Pubitemid 27514944)
29. Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K (2001) Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 104(4):455-460 (Pubitemid 32678277)
30. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A (2002) Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40(5):687-693 (Pubitemid 35282444)
31. Kasai T, Miyauchi K, Yokoyama T, Kajimoto K, Sumiyoshi K, Kubota N, Ikeda E, Daida H (2008) Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis 197(2):612-619. doi:10.1016/j.atherosclerosis.2007.08.030 (Pubitemid 351417907)
32. Li D, Chen K, Sinha N, Zhang X, Wang Y, Sinha AK, Romeo F, Mehta JL (2005) The effects of ppar-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 65(4):907-912. doi:10.1016/j. cardiores.2004.11.027 (Pubitemid 40253577)
33. Takagi T, Yoshida K, Akasaka T, Kaji S, Kawamoto T, Honda Y, Yamamuro A, Hozumi T, Morioka S (2000) Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: A serial intravascular ultrasound study. J Am Coll Cardiol 36(3):731-738. doi:S0735-1097(00)00799-3
34. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457-2471. doi:10.1056/NEJMoa072761 (Pubitemid 46919772)
35. Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD (2010) Heart failure events with rosiglitazone in type 2 diabetes: Data from the record clinical trial. Eur Heart J 31(7):824-831. doi:10.1093/eurheartj/ehp604
36. Coats AJ (2009) Ethical authorship and publishing. Int J Cardiol 131(2):149-150. doi:10.1016/j.ijcard.2008.11.048